Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.

ABSTRACT:

Background

The combination of PD-1/PD-L1 inhibitor and chemotherapy has been clinically confirmed to be beneficial as the first-line treatment of patients with advanced NSCLC. This study aimed to assess the effect of nivolumab + docetaxel versus nivolumab monotherapy in patients with NSCLC after the failure of platinum doublet chemotherapy.

Materials and methods

The efficacy and toxicity of nivolumab + docetaxel combination therapy versus nivolumab monotherapy were compared in this retrospective study. Primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), overall survival (OS), and toxicity.

Results

Between November 2017 and December 2019, 77 patients were included in this study, with 58 pati

SUBMITTER: Wang Y 

PROVIDER: S-EPMC8783906 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature